£13.5M
Calculus Capital led the financing round alongside several institutional investors to support platform development and pipeline progression.
LT
Laverock Therapeutics
Laverock Therapeutics develops a gene silencing platform for programmable advanced therapies.
London, UK—Founded 2021
£13.5MTotal raised
Laverock Therapeutics develops a gene silencing platform to create programmable advanced therapies for human applications. The firm commercialises the gene editing induced gene silencing technology.
Categories
Team
DV
David Venables
CEO
David serves as chief executive of Laverock Therapeutics. He also holds non-executive directorships at NovalGen and Axol Bioscience, alongside board and advisory roles at Concinnity Genetics and the University of Edinburgh.
LinkedIn